Some laboratory aspects of hepatic tolerability of diftalone.
The hepatic tolerability of phthalazine-(2,2-b)-phthalazin-5,12-(7H,14H)-dione (diftalone--administered at the dosage of 750 mg/day p.o. for a mean period of 23 days--has been studied in 40 patients by means of: total plasma protein, albumin, fibrinogen, serum glutamin-oxalacetic transaminase, serum glutamic-pyruvic transaminase, lactic dehydrogenase, creatine phosphokinase, alkaline phosphatase, glycemic curve after glucagon and plasmatic elimination of bromosulphalein. A statistically but not clinically significant increase of the SGPT level is the only change observed.
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism; D004798:Enzymes / Q000097:blood; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008111:Liver Function Tests; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000009:adverse effects*; D013448:Sulfobromophthalein
D001798:Blood Proteins; D004798:Enzymes; D008112:Liver Glycogen; D011724:Pyridazines; D013448:Sulfobromophthalein; D000410:Alanine Transaminase